Trial Profile
A Study in HIV+ Patients With CCR5-tropic Virus and Undetectable Viral Load on a First, Non-Selzentry-Containing Regimen, Switching Them to Once-daily Selzentry (600mg qd) Plus the Same 2 NRTIs Previously Administered
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications Acquired immunodeficiency syndrome; HIV-1 infections
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms SUDS
- 30 Oct 2016 Interim results (n=28) presented at the IDWeek 2016
- 18 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2013 New trial record